Koers Bioqual, Inc. Other OTC
Aandelen
BIOQ
US09065J1016
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 66,15 mln. 61,74 mln. | Omzet 2023 | 62,66 mln. 58,49 mln. | Marktkapitalisatie | 67,98 mln. 63,45 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 5 mln. 4,67 mln. | Nettowinst (verlies) 2023 | - 0 | EV/omzet 2022 | 1,2 x |
Nettoschuld 2022 | 16,54 mln. 15,44 mln. | Nettoschuld 2023 | 11,33 mln. 10,57 mln. | EV/omzet 2023 | 1,27 x |
K/w-verhouding 2022 |
11,9
x | K/w-verhouding 2023 |
81,7
x | Werknemers | - |
Dividendrendement 2022 |
1,43% | Dividendrendement 2023 |
0,66% | Vrij verhandelbaar | 55,92% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 01-08-03 |
Charles C Kirk
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 09-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 87 | 01-01-15 | |
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 01-08-03 |
Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,67% | 42,4 mld. | |
+44,30% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+6,55% | 24,94 mld. | |
-21,66% | 18,96 mld. | |
+29,96% | 12,3 mld. | |
-1,57% | 11,95 mld. | |
+16,03% | 11,32 mld. | |
-4,80% | 11,55 mld. |